Furthermore, an initial screening for TPMT and NUDT15 can predict the drug response in advance, give an appropriate initial dose, and be used for post-mortem detection of severe myelotoxicity, liver failure, and drug resistance to find the genetic causes of ADR and drug resistance (Woillard et al., 2017). Here, TPMT is linked to Hepatic failure.